Celltrion Pharm, Inc.
Financials
Valuation Metrics
Celltrion Pharm, Inc.'s Market Cap is ₩1.6T. At end of 2025 it was ₩2.6T. Ranked #220 of 2,410 in KR market (top 9%), #47 of 1,631 on KOSDAQ (top 3%), #20 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.65T KRW | KR#220/2,410 Sec#20/231 |
| Revenue | 577.99B KRW | KR#572/2,410 Sec#28/231 |
| Net Income | 42.88B KRW | KR#469/2,410 Sec#29/231 |
| Total Assets | 779.18B KRW | KR#565/2,410 Sec#32/231 |
| Net Assets | 449.20B KRW | KR#553/2,410 Sec#33/231 |
| Employees | 920 | KR#276/2,410 Sec#22/231 |
| Value | ||
| P/E | 38.36x | KR#1,379/2,410 Sec#86/231 |
| P/B | 3.66x | KR#2,191/2,410 Sec#185/231 |
| PEG | 1.26x | KR#775/2,410 Sec#49/231 |
| P/S | 2.85x | KR#1,987/2,410 Sec#122/231 |
| EV/EBITDA | 27.97x | KR#1,189/2,410 Sec#72/231 |
| FCF Yield | 4.27% | KR#926/2,410 Sec#55/231 |
| Profitability | ||
| ROE | 9.55% | KR#653/2,410 Sec#45/231 |
| ROA | 5.50% | KR#680/2,410 Sec#56/231 |
| Op. Margin | 10.73% | KR#480/2,410 Sec#43/231 |
| Revenue Growth | 13.88% | KR#720/2,410 Sec#71/231 |
| Earnings Growth | 30.36% | KR#647/2,410 Sec#43/231 |
| Financial Health | ||
| Debt Ratio | 73.46% | KR#1,259/2,410 Sec#151/231 |
| Total Debt | 142.00B KRW | KR#619/2,410 Sec#36/231 |
| FCF | 70.27B KRW | KR#238/2,410 Sec#14/231 |
| Cash | 51.70B KRW | KR#716/2,410 Sec#40/231 |
| Current Ratio | 1.71x | KR#1,024/2,410 Sec#115/231 |
| Net Debt/EBITDA | 1.46x | KR#785/2,410 Sec#54/231 |
| Dividend | ||
| Div. Yield | 0.54% | KR#1,271/2,410 Sec#78/231 |
| Performance | ||
| 1Y Return | -40.78% | KR#1,720/2,410 Sec#141/231 |
| 1M Return | -3.52% | KR#602/2,410 Sec#64/231 |
| From 52W High | -52.68% | KR#1,280/2,410 Sec#100/231 |
| 1Y MDD | -51.78% | KR#1,022/2,410 Sec#82/231 |
| Trading | ||
| Volume | 22,004 shares | KR#1,346/2,410 Sec#136/231 |
| Trading Value | 814.8M KRW | KR#584/2,410 Sec#63/231 |
| Foreign Own. | 4.83% | KR#881/2,410 Sec#79/231 |
| Per Share | ||
| EPS | 966 KRW | KR#736/2,410 Sec#50/231 |
| BPS | 10,117 KRW | KR#995/2,410 Sec#69/231 |
Company Info
This specialized pharmaceutical manufacturing and sales company was established in 2000 and listed on KOSDAQ in 2006. It operates KGMP, US cGMP, and EU-GMP certified facilities in Ochang and Jincheon, Chungcheongbuk-do, producing specialized pharmaceuticals and biopharmaceuticals via PFS production lines. The company holds domestic exclusive sales rights for chemical pharmaceuticals like the liver disease treatment Godex, and 12 biopharmaceuticals, including autoimmune disease treatments and anti-cancer drugs developed by its parent company, Celltrion, while actively pursuing pipeline expansion and technological platform innovation.